Emcure Pharmaceuticals has announced that its Board of Directors, at a meeting held on Tuesday, May 05, 2026, approved the re-appointment of two key managerial figures — Dr. Mukund Gurjar as Whole-time Director and Mr. Satish Mehta as Managing Director — subject to the approval of shareholders. The decisions were made pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and were based on the recommendation of the Nomination and Remuneration Committee. The Board meeting commenced at 12.42 p.m. (IST) and concluded at 2.00 p.m. (IST).

Re-appointment Details

The following table summarises the key details of the two re-appointments approved by the Board:

Both directors have been confirmed as not debarred from holding the office of Director by virtue of any SEBI order, in accordance with BSE Circular No. LIST/COMP/14/2018-19 dated June 20, 2018 and NSE Circular No. NSE/CML/2018/02 dated June 20, 2018, or any other authority.

Profile: Dr. Mukund Gurjar

Dr. Mukund Gurjar has been associated with Emcure Pharmaceuticals since July 23, 2001, and has served as Executive Director and Chief Scientific Officer of the Company. He holds a bachelor's degree in science and a master's degree in science, and qualified as a Doctor of Philosophy in the faculty of science from Nagpur University. He also holds a degree of Doctor of Philosophy from the Queen Elizabeth College, University of London. Prior to joining the Company, Dr. Gurjar worked with the National Chemical Laboratory, Pune for 24 years. He has received a certificate of appreciation in recognition of 17 years of his valued services as an editorial advisory board member for Organic Process Research & Development, American Chemical Society. Dr. Gurjar brings technical and industrial expertise to the Board and the Company. He is not related to any director on the Board of the Company.

Profile: Mr. Satish Mehta

Mr. Satish Mehta is the Managing Director & CEO of Emcure Pharmaceuticals. He is a Postgraduate in Chemistry from Pune University and holds a PGDM (Post Graduate Diploma in Management) from the Indian Institute of Management, Ahmedabad (IIM-A). He started the Company in 1981 with the purpose of providing affordable and high-quality healthcare to patients. Under his leadership, the Emcure Group has established a presence in more than 70 countries through its subsidiaries in the UK, Canada, Singapore, Brazil, and other countries. Mr. Satish Mehta is the father of Mr. Samit Satish Mehta and Mrs. Namita Vikas Thapar, both Whole-time Directors of the Company.

Regulatory Compliance

The intimation has been filed as a revised disclosure under Regulation 30 of the SEBI Listing Regulations, referencing the earlier intimation dated May 05, 2026 with reference number EPL/CS/SE/0040/2026. The disclosure was signed by Amruta Yangalwar, Company Secretary & Compliance Officer (ICSI Membership No.: A25687), on behalf of Emcure Pharmaceuticals.

Emcure Pharmaceuticals Co-CEO has outlined a comprehensive growth strategy for the company, placing research and development at the heart of its long-term ambitions. The Co-CEO specifically identified complex injectables and biosimilars as critical focus areas that are expected to play a pivotal role in driving future growth for the pharmaceutical firm.

R&D Focus: Complex Injectables and Biosimilars

The Co-CEO underscored the strategic importance of investing in complex injectables and biosimilars, segments that require advanced scientific capabilities and regulatory expertise. These therapeutic categories are increasingly significant in both domestic and global pharmaceutical markets, and Emcure Pharmaceuticals' emphasis on them signals a deliberate effort to build differentiated product offerings.

Expansion Through Deals and Acquisitions

Beyond internal R&D, the Co-CEO also discussed the company's growth through external avenues. In-licensing deals have been identified as a key mechanism to broaden the product portfolio and accelerate market access. Additionally, the acquisition of a stake in Zuventus was highlighted as a notable corporate development that forms part of the broader inorganic growth strategy.

The company has also made moves in international markets, with acquisitions in the UK and Canada cited as part of its efforts to strengthen its global footprint. These geographic expansions reflect Emcure Pharmaceuticals' intent to diversify revenue streams and establish a stronger presence in regulated markets outside India.

Strategic Outlook

The Co-CEO's commentary paints a picture of a company pursuing growth on multiple fronts — through scientific innovation in high-value therapeutic segments, strategic partnerships via in-licensing, and targeted acquisitions both domestically and internationally. The combination of R&D investment in complex injectables and biosimilars, alongside inorganic initiatives such as the Zuventus stake and overseas acquisitions, underlines the company's approach to building a diversified and resilient business.